Welcome to the Department of Cellular Therapy which is home to one of Europe’s biggest and most modern GMP facilities for cellular products.

  Dag Josefsen, MD PhD, Head of Department

(Group leaders: E.M. Inderberg and S. Wälchli) has the capacity to undertake complete pre-clinical studies for immunotherapeutic molecules such as vaccines and adoptive T cell transfer (TCR, CAR). It possesses the competence to deliver molecular biology products isolated from patient material (TCR), to perform cellular assays and in vivo animal studies. Finally, innovative tools are also developed in collaboration with academy and private companies.

The Immunomonitoring Lab (Head: E.M. Inderberg) is a heritage from the former research group of Prof. G. Gaudernack and was included in the Department of Cellular Therapy in 2012. It participated to both academic and industrial trials, more information can be found here. 

Our labs are located at the Oslo Cancer Cluster Incubator OCCI

ACT-centre aims at facilitating the development of novel advanced therapy medicinal products (ATMP) and make novel therapies available to Norwegian patients. More information can be found here. 

Congratulations to Dr. Christopher Forcados:

(picture S. Joaquina)

We are happy to annunce that Christopher Forcaods who has been at the unit for 4 years will noon defend his thesis to obtain the degree of Philosophiae Doctor (PhD) deliver by the Medical Faculty of the University of Oslo.

(The hero in action 2 years ago)

You can either come to this address: Auditorium Nye RAD L1 (U1), Bygg L, Radiumhospitalet, Ullernchausseen 70

Or follow him online: 

10:15 AM Trial Lecture:  “Ideas and solutions for in vivo generation of chimeric antigen receptor T cells”

Launch Meeting - Zoom

1:15 PM Public Defense: “Development of novel Chimeric Antigen Receptors against alternative targets”

Launch Meeting - Zoom

More information can be found here

All news